← Leaderboards
Joseph C. Glorioso
University Of Pittsburgh At Pittsburgh
$19,383,290
Attributed
$19,686,654
Total exposure
20
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$60,017,540 · 23
By mechanism
U01$22,752,572 · 3
P01$20,249,745 · 9
R01$8,238,585 · 7
U54$8,169,910 · 3
U18$606,728 · 1
Top collaborators
- Brian M Davis2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- William F. Goins$3,333,127
- Robert L Hendricks$15,975,328
- William Roger Lariviere$1,683,409
- David J. Fink$11,160,913
- George T Somogyi$1,817,016
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorEngineeringGenesLigandsBaseCellsSimplexvirusReceptorMediatingHsv VectorInfectionVirus ReplicationVirusDesignAnimal ModelViralIn VivoClinical TrialsProteinsNeoplastic CellOncolyticGlioblastomaTumor
Grant awards (95)
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction$303,659
P01 · FY2025 · CA · contact PI
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction$288,477
P01 · FY2024 · CA · contact PI
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction$343,160
P01 · FY2023 · CA · contact PI
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice$389,162
R01 · FY2022 · CA · contact PI
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM$348,274
P01 · FY2022 · CA · contact PI
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice$398,001
R01 · FY2021 · CA · contact PI
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM$347,157
P01 · FY2021 · CA · contact PI
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice$398,871
R01 · FY2020 · CA · contact PI
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM$339,204
P01 · FY2020 · CA · contact PI
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice$387,727
R01 · FY2019 · CA · contact PI
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM$321,473
P01 · FY2019 · CA · contact PI
Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice$414,488
R01 · FY2018 · CA · contact PI
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM$357,764
P01 · FY2018 · CA · contact PI
Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector$316,018
R01 · FY2018 · CA · contact PI
Development of a Novel Class of Highly Specific and Effective Oncolytic HSV Vect$369,444
P01 · FY2017 · CA · contact PI
Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector$316,018
R01 · FY2017 · CA · contact PI
Development of a Novel Class of Highly Specific and Effective Oncolytic HSV Vect$368,798
P01 · FY2016 · CA · contact PI
Novel viral tools for control of bladder function and pain$325,355
U18 · FY2016 · EB
Development of a Novel Class of Highly Specific and Effective Oncolytic HSV Vect$365,804
P01 · FY2015 · CA · contact PI
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling$360,853
R01 · FY2015 · NS · contact PI
Novel viral tools for control of bladder function and pain$281,373
U18 · FY2015 · EB
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling$357,142
R01 · FY2014 · NS · contact PI
Development of a Novel Class of Highly Specific and Effective Oncolytic HSV Vect$355,635
P01 · FY2014 · CA · contact PI
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling$348,025
R01 · FY2013 · NS · contact PI
Development of a Novel Class of Highly Specific and Effective Oncolytic HSV Vect$332,981
P01 · FY2013 · CA · contact PI
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling$360,547
R01 · FY2012 · NS · contact PI
Vector delivery to modify the brain tumor and its microenvironment$273,759
P01 · FY2012 · NS · contact PI
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling$360,447
R01 · FY2011 · NS · contact PI
Vector delivery to modify the brain tumor and its microenvironment$273,466
P01 · FY2011 · NS · contact PI
Model Systems for Development of Pain Gene Therapy$1,568,715
P01 · FY2010 · DK · contact PI
NOVEL MODULATORS OF THE VANILLOID RECEPTOR$379,524
P01 · FY2010 · DK · contact PI
Glioma Therapy Using Targeted Oncolytic HSV Vectors$365,663
R01 · FY2010 · CA · contact PI
Vector delivery to modify the brain tumor and its microenvironment$273,181
P01 · FY2010 · NS · contact PI
Model Systems for Development of Pain Gene Therapy$100,000
P01 · FY2010 · DK · contact PI
ADMINISTRATIVE$48,484
P01 · FY2010 · DK · contact PI
Model Systems for Development of Pain Gene Therapy$1,539,351
P01 · FY2009 · DK · contact PI
NOVEL MODULATORS OF THE VANILLOID RECEPTOR$373,060
P01 · FY2009 · DK · contact PI
Glioma Therapy Using Targeted Oncolytic HSV Vectors$359,173
R01 · FY2009 · CA · contact PI
Vector delivery to modify the brain tumor and its microenvironment$209,498
P01 · FY2009 · NS · contact PI
ADMINISTRATIVE$47,548
P01 · FY2009 · DK · contact PI
Model Systems for Development of Pain Gene Therapy$1,495,449
P01 · FY2008 · DK · contact PI
Gene and Cell Therapy of Duchenne Muscular Dystrophy$992,626
U54 · FY2008 · AR · contact PI
NOVEL MODULATORS OF THE VANILLOID RECEPTOR$363,062
P01 · FY2008 · DK · contact PI
Glioma Therapy Using Targeted Oncolytic HSV Vectors$349,393
R01 · FY2008 · CA · contact PI
Functional Genomic Studies of Early Myogenic Differentiation$316,717
U54 · FY2008 · AR · contact PI
Vector delivery to modify the brain tumor and its microenvironment$273,580
P01 · FY2008 · NS · contact PI
Administrative Core$56,031
U54 · FY2008 · AR · contact PI
ADMINISTRATIVE$46,164
P01 · FY2008 · DK · contact PI
Model Systems for Development of Pain Gene Therapy$1,482,497
P01 · FY2007 · DK · contact PI
Gene and Cell Therapy of Duchenne Muscular Dystrophy$724,448
U54 · FY2007 · AR · contact PI
NOVEL MODULATORS OF THE VANILLOID RECEPTOR$396,882
P01 · FY2007 · DK · contact PI
Glioma Therapy Using Targeted Oncolytic HSV Vectors$346,627
R01 · FY2007 · CA · contact PI
Functional Genomic Studies of Early Myogenic Differentiation$71,708
U54 · FY2007 · AR · contact PI
ADMINISTRATIVE$51,268
P01 · FY2007 · DK · contact PI
MODEL SYSTEMS FOR DEVELOPMENT OF PAIN GENE THERAPY$1,579,985
P01 · FY2006 · DK · contact PI
Gene and Cell Therapy of Duchenne Muscular Dystrophy$1,531,364
U54 · FY2006 · AR · contact PI
NOVEL MODULATORS OF THE VANILLOID RECEPTOR$413,393
P01 · FY2006 · DK · contact PI
Glioma Therapy Using Targeted Oncolytic HSV Vectors$346,841
R01 · FY2006 · CA · contact PI
ADMINISTRATIVE$51,261
P01 · FY2006 · DK · contact PI
Cardiovascular Gene Therapy Center$3,376,374
U01 · FY2005 · HL
Gene and Cell Therapy of Duchenne Muscular Dystrophy$1,495,446
U54 · FY2005 · AR
Heme Oxygenas Gene Therapy of Heart Ischemia-reperfusion$369,744
U01 · FY2005 · HL
Retargeting HSV-1 Vectors to Motor Neurons$355,063
R01 · FY2005 · NS
Administrative Core$76,467
U01 · FY2005 · HL
CARDIOVASCULAR GENE THERAPY CENTER$3,449,355
U01 · FY2004 · HL
Gene and Cell Therapy of Duchenne Muscular Dystrophy$1,474,970
U54 · FY2004 · AR
Retargeting HSV-1 Vectors to Motor Neurons$355,063
R01 · FY2004 · NS
CARDIOVASCULAR GENE THERAPY CENTER$72,092
U01 · FY2004 · HL
CARDIOVASCULAR GENE THERAPY CENTER$3,580,156
U01 · FY2003 · HL
Gene and Cell Therapy of Duchenne Muscular Dystrophy$1,506,600
U54 · FY2003 · AR
MODEL SYSTEMS TOWARD DEVELOPMENT OF HUMAN GENE THERAPY$1,038,500
P01 · FY2003 · DK
Retargeting HSV-1 Vectors to Motor Neurons$355,063
R01 · FY2003 · NS
CARDIOVASCULAR GENE THERAPY CENTER$12,914
U01 · FY2003 · HL
Functional Genomics Studies of Early Myogenic Differentiation$0
U54 · FY2003 · AR
CARDIOVASCULAR GENE THERAPY CENTER$3,684,088
U01 · FY2002 · HL
MODEL SYSTEMS TOWARD DEVELOPMENT OF HUMAN GENE THERAPY$1,010,583
P01 · FY2002 · DK
Retargeting HSV-1 Vectors to Motor Neurons$355,063
R01 · FY2002 · NS
Targeting HSV vectors$292,370
U01 · FY2002 · HL
Targeting HSV vectors$292,370
U01 · FY2002 · HL
MODIFICATION OF EFFERENT IMMUNOLOGICAL RESPONSES$210,131
P01 · FY2002 · NS
GENE THERAPY FOR DIABETIC NEUROPATHY USING HSV-NGF$103,677
P01 · FY2002 · DK
CARDIOVASCULAR GENE THERAPY CENTER$74,708
U01 · FY2002 · HL
CARDIOVASCULAR GENE THERAPY CENTER$3,237,996
U01 · FY2001 · HL
MODEL SYSTEMS TOWARD DEVELOPMENT OF HUMAN GENE THERAPY$986,451
P01 · FY2001 · DK
CARDIOVASCULAR GENE THERAPY CENTER$347,629
U01 · FY2001 · HL
Targeting HSV vectors$292,370
U01 · FY2001 · HL
Targeting HSV vectors$292,370
U01 · FY2001 · HL
HSV GENE VECTORS FOR TREATMENT OF ARTHRITIS$227,255
R01 · FY2001 · AR
GENE THERAPY FOR DIABETIC NEUROPATHY USING HSV-NGF$103,677
P01 · FY2001 · DK
CARDIOVASCULAR GENE THERAPY CENTER$3,009,199
U01 · FY2000 · HL
MODEL SYSTEMS TOWARD DEVELOPMENT OF HUMAN GENE THERAPY$959,390
P01 · FY2000 · DK
Targeting HSV vectors$292,370
U01 · FY2000 · HL
HSV GENE VECTORS FOR TREATMENT OF ARTHRITIS$221,064
R01 · FY2000 · AR
HSV LATENCY AND MECHANISMS OF GENE SILENCING$195,018
R01 · FY2000 · GM
GENE THERAPY FOR DIABETIC NEUROPATHY USING HSV-NGF$155,379
P01 · FY2000 · DK